Frequencies of mutation in ASXL1, RUNX1, DNMT3A, NPM1, FLT3-ITD and TP53 in the 125 AML-MRC patients and according to the karyotypes (A) and to the cytogenetic risk groups(B). This evidence concerns the gene RUNX1 and acute myeloid leukemia.